Effects of Mesalamine Combined with Live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules on Intestinal Mucosa Barrier Function and Intestinal Microbiota in Mildly Active Crohn’s Disease Patients

Figures & data

Table 1. General data between the two groups.

Indicators	The control group (n = 48)	The observation group (n = 48)	p Value
Age (years)	38.75 ± 7.40	39.56 ± 8.16	0.611
Gender (male/female)	28/20	26/22	0.681
Duration of disease (year)	3.48 ± 1.50	3.65 ± 1.48	0.569
CDAI score	178. 83 ± 17.16	178. 94 ± 17.91	0.934
Lesion site			0.686
Terminal ileum	11 (22.92)	10 (20.83)
Colon	25 (52.08)	22 (45.83)
Ileocolon	12 (25.00)	16 (33.33)

Table 2. Clinical efficacy between the two groups [cases (%)].

Group	Clinically relieved	Effective	Ineffective	Total effective rate	p Value
The control group (n = 48)	26 (54.17)	15 (31.25)	7 (14.58)	41 (85.42)	0.027
The observation group (n = 48)	34 (70.83)	13 (27.08)	1 (2.09)	47 (97.91)

Figure 1. Changes In the number of intestinal microbiota between the control and observation groups. (A) Comparison of the number of intestinal L. acidophilus before and after treatment in the two groups. (B) Comparison of the number of intestinal B. longum before and after treatment in the two groups. (C) Comparison of the number of intestinal B. vulgatus before and after treatment in the two groups. *p < 0.05.

Figure 2. Nutrition indicators between the control and observation groups. (A) Comparison of serum ALB levels before and after treatment in the two groups. (B) Comparison of serum TLB levels before and after treatment in the two groups. *p < 0.05.

Figure 3. Changes In the levels of inflammatory factors between the control and observation groups. (A) Comparison of serum TNF-α levels before and after treatment in the two groups. (B) Comparison of serum IL-6 levels before and after treatment in the two groups. (C) Comparison of serum IL-10 levels before and after treatment in the two groups. (D) Comparison of serum CRP levels before and after treatment in the two groups. *p < 0.05.

Figure 4. Changes In immune function indicators between the control and observation groups. (A) Comparison of CD4+ before and after treatment in the two groups. (B) Comparison of CD8+ before and after treatment in the two groups. (C) Comparison of CD4+/CD8+ before and after treatment in the two groups. *p < 0.05.

Figure 5. Changes in intestinal mucosal barrier function indicators and lactulose/mannitol ratio between the control and observation groups. (A) Comparison of serum ET levels before and after treatment in the two groups. (B) Comparison of serum D-lactate levels before and after treatment in the two groups. (C) Comparison of serum DAO levels before and after treatment in the two groups. (D) Comparison of urine L/M before and after treatment in the two groups. *p < 0.05.

Table 3. Adverse reactions between the two groups [cases (%)].

Group	Dizziness	Nausea	Rash	Total incidence rate	p Value
The control group (n = 48)	1 (2.08)	1 (2.08)	1 (2.08)	3 (6.25)	0.460
The observation group (n = 48)	1 (2.08)	3 (6.25)	1 (2.08)	5 (10.42)